Dostarlimab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dostarlimab" in English language version.

refsWebsite

Global rank English rank

26web.archive.org

1^st place

18nih.gov

4^th place

12doi.org

2^nd place

7fda.gov

447^th place

338^th place

6semanticscholar.org

11^th place

8^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

3europa.eu

68^th place

117^th place

2tga.gov.au

3,984^th place

2,622^nd place

2worldcat.org

5^th place

2handle.net

102^nd place

76^th place

2gsk.com

low place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1prnewswire.com

406^th place

258^th place

1globenewswire.com

2,614^th place

1,549^th place

1cancer.gov

1,684^th place

1,350^th place

1wikimedia.org

low place

1stjude.org

low place

1jamanetwork.com

2,650^th place

3,409^th place

1newatlas.com

5,636^th place

3,692^nd place

1ascopubs.org

low place

1mayoclinic.org

1,610^th place

1,279^th place

1medscape.com

719^th place

636^th place

1washingtonpost.com

34^th place

27^th place

1sciencefocus.com

low place

8,501^st place

1ama-assn.org

3,257^th place

3,398^th place

1drugs.com

399^th place

333^rd place

ama-assn.org

searchusan.ama-assn.org

"Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab" (PDF). searchusan.ama-assn.org. 24 September 2018. Archived (PDF) from the original on 24 September 2018. Retrieved 13 March 2023.

ascopubs.org

Cercek A, Bachet JB, Capdevila J, Starling N, Chen EX, Di Bartolomeo M, et al. (1 June 2023). "Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer". Journal of Clinical Oncology. 41 (16_suppl): TPS3639. doi:10.1200/JCO.2023.41.16_suppl.TPS3639. ISSN 0732-183X.

canada.ca

"Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.

cancer.gov

"Endometrial Cancer Treatment". National Cancer Institute. 23 May 2022. Archived from the original on 3 September 2014. Retrieved 28 July 2022.

clinicaltrials.gov

Clinical trial number NCT02715284 for "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov
Clinical trial number NCT03981796 for "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" at ClinicalTrials.gov
Clinical trial number NCT03602859 for "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" at ClinicalTrials.gov

doi.org

Kasherman L, Ahrari S, Lheureux S (March 2021). "Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer". Future Oncology. 17 (8): 877–892. doi:10.2217/fon-2020-0655. PMID 33251877. S2CID 227234713.
Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, et al. (June 2021). "Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology". Biomedicines. 9 (6): 632. doi:10.3390/biomedicines9060632. PMC 8228955. PMID 34199461.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797. S2CID 249395846.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. (November 2020). "Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial". JAMA Oncology. 6 (11): 1766–1772. doi:10.1001/jamaoncol.2020.4515. PMC 7530821. PMID 33001143. Archived from the original on 23 June 2022. Retrieved 1 August 2022.
Cercek A, Bachet JB, Capdevila J, Starling N, Chen EX, Di Bartolomeo M, et al. (1 June 2023). "Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer". Journal of Clinical Oncology. 41 (16_suppl): TPS3639. doi:10.1200/JCO.2023.41.16_suppl.TPS3639. ISSN 0732-183X.
Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. (May 2022). "Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial". Clinical Lung Cancer. 23 (7): e415 – e427. doi:10.1016/j.cllc.2022.05.013. hdl:10668/22104. PMID 35729005. S2CID 249032757.
Costa B, Vale N (July 2022). "Dostarlimab: A Review". Biomolecules. 12 (8): 1031. doi:10.3390/biom12081031. PMC 9331682. PMID 35892341.
Park UB, Jeong TJ, Gu N, Lee HT, Heo YS (April 2022). "Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy". Biochemical and Biophysical Research Communications. 599: 31–37. doi:10.1016/j.bbrc.2022.02.026. PMID 35168061. S2CID 246712420.
Aghanejad A, Bonab SF, Sepehri M, Haghighi FS, Tarighatnia A, Kreiter C, et al. (May 2022). "A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors". International Journal of Biological Macromolecules. 207: 592–610. doi:10.1016/j.ijbiomac.2022.03.057. PMID 35296439. S2CID 247461488.
Green AK, Feinberg J, Makker V (March 2020). "A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40 (40): 238–244. doi:10.1200/EDBK_280503. PMID 32213091. S2CID 214682066.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797.
Bodurtha Smith AJ, Pena D, Ko E (February 2022). "Insurance-Mediated Disparities in Gynecologic Oncology Care". Obstetrics & Gynecology. 139 (2): 305–312. doi:10.1097/AOG.0000000000004643. PMC 8759538. PMID 34991133.

drugs.com

"Jemperli Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 June 2022. Retrieved 26 July 2022.

europa.eu

ema.europa.eu

"Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Archived from the original on 14 May 2022. Retrieved 16 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Jemperli: Pending EC decision". European Medicines Agency (EMA) (Press release). 25 February 2021. Archived from the original on 23 April 2021. Retrieved 22 April 2021.

ec.europa.eu

"Jemperli Product information". Union Register of medicinal products. Archived from the original on 5 March 2023. Retrieved 3 March 2023.

fda.gov

"FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Archived from the original on 22 April 2021. Retrieved 22 April 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA). 9 February 2023. Archived from the original on 10 February 2023. Retrieved 10 February 2023. This article incorporates text from this source, which is in the public domain.
"FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors". U.S. Food and Drug Administration (FDA). 18 August 2021. Archived from the original on 18 August 2021. Retrieved 18 August 2021. This article incorporates text from this source, which is in the public domain.
"FDA Roundup: August 1, 2023" (Press release). U.S. Food and Drug Administration (FDA). 1 August 2023. Retrieved 2 August 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer" (Press release). U.S. Food and Drug Administration (FDA). 31 July 2023. Retrieved 2 August 2023. This article incorporates text from this source, which is in the public domain.
"FDA Roundup: August 2, 2024". U.S. Food and Drug Administration (Press release). 2 August 2024. Retrieved 8 August 2024. This article incorporates text from this source, which is in the public domain.
"Drug Trial Snapshot: Jemperli". U.S. Food and Drug Administration (FDA). 13 March 2023. Archived from the original on 13 March 2023. Retrieved 13 March 2023. This article incorporates text from this source, which is in the public domain.

globenewswire.com

"European Commission Approves Jemperli (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe" (Press release). AnaptysBio Inc. 23 April 2021. Archived from the original on 17 July 2021. Retrieved 13 July 2021 – via GlobeNewswire.

gsk.com

admin-usv5.production.gsk.com

"GSK receives FDA accelerated approval for Jemperli (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors". GlaxoSmithKline (Press release). 17 August 2021. Archived from the original on 10 June 2022. Retrieved 18 August 2021.

us.gsk.com

"Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". GSK (Press release). Archived from the original on 27 December 2019. Retrieved 1 January 2020.

handle.net

hdl.handle.net

Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. (May 2022). "Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial". Clinical Lung Cancer. 23 (7): e415 – e427. doi:10.1016/j.cllc.2022.05.013. hdl:10668/22104. PMID 35729005. S2CID 249032757.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Jemperli". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

jamanetwork.com

Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. (November 2020). "Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial". JAMA Oncology. 6 (11): 1766–1772. doi:10.1001/jamaoncol.2020.4515. PMC 7530821. PMID 33001143. Archived from the original on 23 June 2022. Retrieved 1 August 2022.

mayoclinic.org

"Acute liver failure - Symptoms and causes". Mayo Clinic. Archived from the original on 27 June 2022. Retrieved 4 August 2022.

medscape.com

Mulcahy N (22 April 2021). "FDA Approves New Immunotherapy for Endometrial Cancer". Medscape. Archived from the original on 22 April 2021. Retrieved 23 April 2021.

newatlas.com

Thompson B (5 June 2024). "100% of cancer patients cured long-term in 'remarkable' human trial". New Atlas. Retrieved 8 June 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kasherman L, Ahrari S, Lheureux S (March 2021). "Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer". Future Oncology. 17 (8): 877–892. doi:10.2217/fon-2020-0655. PMID 33251877. S2CID 227234713.
Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, et al. (June 2021). "Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology". Biomedicines. 9 (6): 632. doi:10.3390/biomedicines9060632. PMC 8228955. PMID 34199461.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797. S2CID 249395846.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. (November 2020). "Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial". JAMA Oncology. 6 (11): 1766–1772. doi:10.1001/jamaoncol.2020.4515. PMC 7530821. PMID 33001143. Archived from the original on 23 June 2022. Retrieved 1 August 2022.
Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. (May 2022). "Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial". Clinical Lung Cancer. 23 (7): e415 – e427. doi:10.1016/j.cllc.2022.05.013. hdl:10668/22104. PMID 35729005. S2CID 249032757.
Costa B, Vale N (July 2022). "Dostarlimab: A Review". Biomolecules. 12 (8): 1031. doi:10.3390/biom12081031. PMC 9331682. PMID 35892341.
Park UB, Jeong TJ, Gu N, Lee HT, Heo YS (April 2022). "Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy". Biochemical and Biophysical Research Communications. 599: 31–37. doi:10.1016/j.bbrc.2022.02.026. PMID 35168061. S2CID 246712420.
Aghanejad A, Bonab SF, Sepehri M, Haghighi FS, Tarighatnia A, Kreiter C, et al. (May 2022). "A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors". International Journal of Biological Macromolecules. 207: 592–610. doi:10.1016/j.ijbiomac.2022.03.057. PMID 35296439. S2CID 247461488.
Green AK, Feinberg J, Makker V (March 2020). "A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40 (40): 238–244. doi:10.1200/EDBK_280503. PMID 32213091. S2CID 214682066.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797.
Bodurtha Smith AJ, Pena D, Ko E (February 2022). "Insurance-Mediated Disparities in Gynecologic Oncology Care". Obstetrics & Gynecology. 139 (2): 305–312. doi:10.1097/AOG.0000000000004643. PMC 8759538. PMID 34991133.

ncbi.nlm.nih.gov

Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, et al. (June 2021). "Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology". Biomedicines. 9 (6): 632. doi:10.3390/biomedicines9060632. PMC 8228955. PMID 34199461.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797. S2CID 249395846.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. (November 2020). "Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial". JAMA Oncology. 6 (11): 1766–1772. doi:10.1001/jamaoncol.2020.4515. PMC 7530821. PMID 33001143. Archived from the original on 23 June 2022. Retrieved 1 August 2022.
Costa B, Vale N (July 2022). "Dostarlimab: A Review". Biomolecules. 12 (8): 1031. doi:10.3390/biom12081031. PMC 9331682. PMID 35892341.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797.
Bodurtha Smith AJ, Pena D, Ko E (February 2022). "Insurance-Mediated Disparities in Gynecologic Oncology Care". Obstetrics & Gynecology. 139 (2): 305–312. doi:10.1097/AOG.0000000000004643. PMC 8759538. PMID 34991133.

dailymed.nlm.nih.gov

"Jemperli- dostarlimab injection". DailyMed. Archived from the original on 1 March 2022. Retrieved 28 April 2021.

prnewswire.com

"FDA grants accelerated approval for GSK's Jemperli (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer" (Press release). GlaxoSmithKline. 22 April 2021. Archived from the original on 23 April 2021. Retrieved 22 April 2021 – via PR Newswire.

sciencefocus.com

"The 19 most mind-blowing science stories of 2022". BBC Science Focus Magazine. Archived from the original on 1 February 2023. Retrieved 19 February 2023.

semanticscholar.org

api.semanticscholar.org

Kasherman L, Ahrari S, Lheureux S (March 2021). "Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer". Future Oncology. 17 (8): 877–892. doi:10.2217/fon-2020-0655. PMID 33251877. S2CID 227234713.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. (June 2022). "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer". The New England Journal of Medicine. 386 (25): 2363–2376. doi:10.1056/NEJMoa2201445. PMC 9492301. PMID 35660797. S2CID 249395846.
Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. (May 2022). "Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial". Clinical Lung Cancer. 23 (7): e415 – e427. doi:10.1016/j.cllc.2022.05.013. hdl:10668/22104. PMID 35729005. S2CID 249032757.
Park UB, Jeong TJ, Gu N, Lee HT, Heo YS (April 2022). "Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy". Biochemical and Biophysical Research Communications. 599: 31–37. doi:10.1016/j.bbrc.2022.02.026. PMID 35168061. S2CID 246712420.
Aghanejad A, Bonab SF, Sepehri M, Haghighi FS, Tarighatnia A, Kreiter C, et al. (May 2022). "A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors". International Journal of Biological Macromolecules. 207: 592–610. doi:10.1016/j.ijbiomac.2022.03.057. PMID 35296439. S2CID 247461488.
Green AK, Feinberg J, Makker V (March 2020). "A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40 (40): 238–244. doi:10.1200/EDBK_280503. PMID 32213091. S2CID 214682066.

stjude.org

"What is a Solid Tumor?". www.stjude.org. Archived from the original on 30 January 2022. Retrieved 4 August 2022.

tga.gov.au

"Jemperli APMDS". Therapeutic Goods Administration (TGA). 2 March 2022. Archived from the original on 19 March 2022. Retrieved 5 March 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.

washingtonpost.com

Bellware K, Bernstein L (10 June 2022). "Eye-catching cancer drug trial results have researchers asking: What's next?". The Washington Post. ISSN 0190-8286. Archived from the original on 12 June 2022. Retrieved 15 June 2022.

web.archive.org

"Jemperli APMDS". Therapeutic Goods Administration (TGA). 2 March 2022. Archived from the original on 19 March 2022. Retrieved 5 March 2022.
"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
"Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.
"Summary Basis of Decision (SBD) for Jemperli". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
"Jemperli- dostarlimab injection". DailyMed. Archived from the original on 1 March 2022. Retrieved 28 April 2021.
"FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Archived from the original on 22 April 2021. Retrieved 22 April 2021. This article incorporates text from this source, which is in the public domain.
"FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA). 9 February 2023. Archived from the original on 10 February 2023. Retrieved 10 February 2023. This article incorporates text from this source, which is in the public domain.
"Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Archived from the original on 14 May 2022. Retrieved 16 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Jemperli Product information". Union Register of medicinal products. Archived from the original on 5 March 2023. Retrieved 3 March 2023.
"FDA grants accelerated approval for GSK's Jemperli (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer" (Press release). GlaxoSmithKline. 22 April 2021. Archived from the original on 23 April 2021. Retrieved 22 April 2021 – via PR Newswire.
"European Commission Approves Jemperli (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe" (Press release). AnaptysBio Inc. 23 April 2021. Archived from the original on 17 July 2021. Retrieved 13 July 2021 – via GlobeNewswire.
"Endometrial Cancer Treatment". National Cancer Institute. 23 May 2022. Archived from the original on 3 September 2014. Retrieved 28 July 2022.
"FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors". U.S. Food and Drug Administration (FDA). 18 August 2021. Archived from the original on 18 August 2021. Retrieved 18 August 2021. This article incorporates text from this source, which is in the public domain.
"GSK receives FDA accelerated approval for Jemperli (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors". GlaxoSmithKline (Press release). 17 August 2021. Archived from the original on 10 June 2022. Retrieved 18 August 2021.
Cancer Research UK (30 July 2014), Diagram showing a monoclonal antibody attached to a cancer cell., archived from the original on 6 August 2022, retrieved 4 August 2022
"What is a Solid Tumor?". www.stjude.org. Archived from the original on 30 January 2022. Retrieved 4 August 2022.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. (November 2020). "Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial". JAMA Oncology. 6 (11): 1766–1772. doi:10.1001/jamaoncol.2020.4515. PMC 7530821. PMID 33001143. Archived from the original on 23 June 2022. Retrieved 1 August 2022.
"Acute liver failure - Symptoms and causes". Mayo Clinic. Archived from the original on 27 June 2022. Retrieved 4 August 2022.
"Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". GSK (Press release). Archived from the original on 27 December 2019. Retrieved 1 January 2020.
Mulcahy N (22 April 2021). "FDA Approves New Immunotherapy for Endometrial Cancer". Medscape. Archived from the original on 22 April 2021. Retrieved 23 April 2021.
"Drug Trial Snapshot: Jemperli". U.S. Food and Drug Administration (FDA). 13 March 2023. Archived from the original on 13 March 2023. Retrieved 13 March 2023. This article incorporates text from this source, which is in the public domain.
Bellware K, Bernstein L (10 June 2022). "Eye-catching cancer drug trial results have researchers asking: What's next?". The Washington Post. ISSN 0190-8286. Archived from the original on 12 June 2022. Retrieved 15 June 2022.
"The 19 most mind-blowing science stories of 2022". BBC Science Focus Magazine. Archived from the original on 1 February 2023. Retrieved 19 February 2023.
"Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab" (PDF). searchusan.ama-assn.org. 24 September 2018. Archived (PDF) from the original on 24 September 2018. Retrieved 13 March 2023.
"Jemperli: Pending EC decision". European Medicines Agency (EMA) (Press release). 25 February 2021. Archived from the original on 23 April 2021. Retrieved 22 April 2021.
"Jemperli Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 June 2022. Retrieved 26 July 2022.

wikimedia.org

commons.wikimedia.org

Cancer Research UK (30 July 2014), Diagram showing a monoclonal antibody attached to a cancer cell., archived from the original on 6 August 2022, retrieved 4 August 2022

worldcat.org

search.worldcat.org

Cercek A, Bachet JB, Capdevila J, Starling N, Chen EX, Di Bartolomeo M, et al. (1 June 2023). "Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer". Journal of Clinical Oncology. 41 (16_suppl): TPS3639. doi:10.1200/JCO.2023.41.16_suppl.TPS3639. ISSN 0732-183X.
Bellware K, Bernstein L (10 June 2022). "Eye-catching cancer drug trial results have researchers asking: What's next?". The Washington Post. ISSN 0190-8286. Archived from the original on 12 June 2022. Retrieved 15 June 2022.